Massive Counterfeit Cancer Drug Racket Busted in India; 17 Arrested
In a major blow to public health safety, Delhi Police have dismantled a sophisticated, multi-state syndicate involved in the trafficking and manufacturing of counterfeit and illegally diverted anti-cancer medications. The operation, which spanned several major Indian cities, resulted in 17 arrests and the seizure of medical supplies valued at approximately Rs 90 million (£688,188).
A Web of Deceit
The syndicate allegedly operated through a combination of theft, diversion, and outright fraud. According to investigators, the network procured drugs through three primary channels: stealing genuine vials and packaging from private hospitals; diverting legitimate supplies from government warehouses; and manufacturing counterfeit versions from scratch.
"The accused themselves made counterfeit drugs by imitating the vials and the packing and using fake batch numbers," a senior police official stated. "They filled them with sterilized water and sold them as real drugs to desperate patients at discounted prices."
The recovered haul included life-saving immunotherapy and targeted therapy drugs—such as Keytruda, Opdyta, and Darzalex—which carry high market prices ranging from Rs 15,000 to Rs 200,000 per dose.
Coordinated Raids
The investigation, which began on 22 June following a tip-off to the Crime Branch, culminated on 11 July with simultaneous raids across Delhi, Haryana, Uttar Pradesh, Mumbai, and Hyderabad. In addition to 588 filled vials, police seized 3,021 units of various other medicines, along with packaging equipment such as thermocol boxes and bubble wrap. Forensic evidence suggests the suspects used chemicals like acetone to erase batch numbers and retail pricing from authentic packaging to obscure the drug’s origin.
The operation involved individuals with specialized medical backgrounds, including nursing staff and former pharmaceutical firm employees. Key figures, such as an oncology department in-charge and a former dental technician, were reportedly central to misappropriating the vials before they reached the black market.
Impact on Global Reputation
The discovery of this illicit network serves as a significant setback to India’s aspiration to move beyond its role as the "pharmacy of the world" toward becoming a hub for global pharmaceutical innovation.
While India remains the world’s third-largest producer of drugs by volume, its reputation has been under intense scrutiny following international scandals involving tainted cough syrups linked to the deaths of over 140 children in Africa and Central Asia.
With over 500,000 foreign nationals traveling to India for medical treatment annually—many seeking affordable oncology care—the prevalence of counterfeit medication poses a grave threat to both domestic patients and the country’s growing medical tourism industry. As the government pivots toward a focus on quality and reliability for 2026, this crackdown highlights the ongoing challenges in regulating a massive and complex pharmaceutical supply chain.
